| Project/Area Number |
15K21533
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Radiation science
Orthopaedic surgery
|
|---|
| Research Institution | Kobe Gakuin University |
|---|
Principal Investigator |
Andoh Tooru 神戸学院大学, 薬学部, 助手 (50639226)
|
|---|
| Research Collaborator |
Fujimoto Takuya 兵庫県立がんセンター, 整形外科
Sudo Tamotsu 兵庫県立がんセンター, 研究部
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | ホウ素中性子線捕捉療法 / 明細胞肉腫 / 軟部肉腫 / p-borono-L-phenylalanine / LAT1 / ホウ素中性子捕捉療法 / L-BPA / LAT-1 |
|---|
| Outline of Final Research Achievements |
L-type amino acid transporter-1 (LAT1) carries p-borono-L-phenylalanine (L-BPA) into tumor cells, mediating the efficacy of BNCT. Malignant tumor cells preferentially take up L-BPA because its chemical structure is similar to that of tyrosine. Indeed, our previous study demonstrated that Clear cell sarcoma (CCS) has the ability to highly take up L-BPA in vitro and in vivo. However, difference of antitumor effect among CCS cell lines based on an uptake of L-BPA. Thus, BNCT utilizing L-BPA could be a novel clinical option to treat CCS, provided that this research could reveal the mechanism of uptake.
LAT-1 was observed in each cell line by westan-blott method. The uptake of 10B in four CCS cell lines was inhibited by pretreatment with BCH. The inhibitory efficiency was 31.6 to 55.6%, each CCS cell line may correlate with expression level. These results indicated that LAT-1 was expressed in CCS cell lines and played a key role in uptake of L-BPA.
|
